Indeed, a weaker DYRK1A expression was correlated with a worse overall survival in breast cancer patients [27] and a poorer prognosis in CRC and GBM patients [62,86], whereas more DYRK1A was associated with a reduced survival time in patients with lung cancer [67]. Here, DYRK1A is linked to lung carcinoma.